

Product Update

azithromycin 500mg powder for solution for infusion (Zedbac[®]) (No. 950/14)

Aspire Pharma Limited

07 March 2014

The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs) on its use in NHS Scotland. The advice is summarised as follows:

ADVICE: following an abbreviated submission:

azithromycin (Zedbac[®]) is accepted for use within NHS Scotland.

Indication under review: the treatment of community acquired pneumonia (CAP) and pelvic inflammatory disease (PID) due to susceptible organisms in adult patients where initial intravenous therapy is required.

Consideration should be given to official guidance regarding the appropriate use of antibacterial agents.

This is the first intravenous formulation of azithromycin to be made available in the UK.

The intravenous formulation is significantly more expensive than the oral preparation of azithromycin, but it is intended only for short-term use and on the advice of local microbiologists or specialists in infectious diseases.

Advice context:

No part of this advice may be used without the whole of the advice being quoted in full.

This advice represents the view of the Scottish Medicines Consortium and was arrived at after evaluation of the evidence submitted by the company. It is provided to inform the considerations of Area Drug & Therapeutics Committees and NHS Boards in Scotland in determining medicines for local use or local formulary inclusion. This advice does not override the individual responsibility of health professionals to make decisions in the exercise of their clinical judgement in the circumstances of the individual patient, in consultation with the patient and/or guardian or carer.

This assessment is based on data submitted by the applicant company up to and including 14 February 2014.

Chairman
Scottish Medicines Consortium

Published 07 April 2014